Addex Therapeutics
ADXN
8 hedge funds and large institutions have $243K invested in Addex Therapeutics in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 6 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.41% less ownership
Funds ownership: 0.47% → 0.06% (-0.41%)
20% less funds holding
Funds holding: 10 → 8 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
80% less capital invested
Capital invested by funds: $1.21M → $243K (-$966K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$53.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$21.1K |
| 3 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$19.8K |
| 4 |
SG
StoneX Group
New York
|
+$11.1K |
| 5 |
VF
Virtu Financial
New York
|
+$10.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$3.37M |
| 2 |
AC
Armistice Capital
New York
|
-$256K |
| 3 |
NLVP
New Leaf Venture Partners
New York
|
-$40K |
| 4 |
FIA
FNY Investment Advisers
New York
|
-$17K |
| 5 |
Millennium Management
New York
|
-$16K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NMC
1
NEA Management Company
Timonium,
Maryland
| $113K | -$3.37M | -228,435 | -81% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $45.4K | +$53.3K | +3,607 | New |
|
|
3
Citadel Advisors
Miami,
Florida
| $26.1K | +$21.1K | +1,429 | +223% |
|
|
OMC
4
Old Mission Capital
Chicago,
Illinois
| $16.9K | +$19.8K | +1,341 | New |
|
5
Renaissance Technologies
New York
| $14K | -$5.64K | -382 | -26% |
|
|
SG
6
StoneX Group
New York
| $9.45K | +$11.1K | +750 | New |
|
7
UBS Group
Zurich,
Switzerland
| $9.15K | +$5.52K | +374 | +106% |
|
|
VF
8
Virtu Financial
New York
| $9K | +$10.4K | +706 | New |
|
|
AC
9
Armistice Capital
New York
| – | -$256K | -16,000 | Closed |
|
|
NLVP
10
New Leaf Venture Partners
New York
| – | -$40K | -2,500 | Closed |
|
|
FIA
11
FNY Investment Advisers
New York
| – | -$17K | -1,125 | Closed |
|
|
12
Millennium Management
New York
| – | -$16K | -998 | Closed |
|
|
TSS
13
Two Sigma Securities
New York
| – | -$10K | -604 | Closed |
|
ADXN Hedge Fund Activity: Q4 2022 in Review
8 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Addex Therapeutics (ADXN) for Q4 2022, worth a combined $243K — down 80% from $1.21M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ADXN and 4 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $53.3K. The largest seller was NEA Management Company, cutting an estimated $3.37M.
- 8 institutional investors held Addex Therapeutics (ADXN) as of Q4 2022, down from 10 in Q3 2022.
- Funds reported $243K of Addex Therapeutics stock for Q4 2022, down 80% quarter-over-quarter.
- 4 funds opened new Addex Therapeutics positions in Q4 2022 and 6 closed out, a net change of -2 holders.
- The largest Addex Therapeutics buyer in Q4 2022 was Susquehanna International Group, an estimated $53.3K added.
- The largest Addex Therapeutics seller in Q4 2022 was NEA Management Company, an estimated $3.37M sold.
Based on aggregated 13F filings for Q4 2022.